The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Where are we now??
The truth is no-one knows except the insiders.
We all know they needed cash in March. March came and went with no deal, and not even the PE investor offering anything.
Radio silence means they have no plan to tell us, the owners of the company. No-one seems to want to lend them money which also tells me their deal is non existent otherwise they would have wanted to tell us.
It's a bad, bad situation and it's getting more and more absurd. ( to quote the man)
Looks like they've failed
It was very badly handled. By Roq or the Broker no-one knows. In a presentation 6 months or so ago Ajan did say that they had enough money to run operations till the end of March. This is public info and anyone can go back to see that live presentation.
I emailed management at the end of March regarding this but with no reply. On hind sight this was their blackout period.
What we can take from this is that there is no meaningful conversations with a PE investor, and the big Pharma discussions are delayed longer than the Co chad envisaged. Not dead by a long way but very disappointing.
I did notice that in their last announcement they did say that they would tell the market "when a binding agreement was " finalized as opposed to their last one which said, If and when, ( or words to that effect)
One question I have is , where are the bulletin board comments regarding the miss information as to the placement price that they referred to????
I can't find them. Please help if you can
ROQ last placed shares at a large premium to the then current share price. I believe it was 8 pence and placement at 14 pence. I also believe that Ajan , a VC fund and a Japanese Pharma Co took this Placement.
The management have said that they have the cash till March next year when another placement will probably be transacted. I don't believe that this Placement will dilute current share holders either.
What I'm really expecting though is one or two major announcements before end of year which should finally propel the shares to new levels. So all anticipation is for the coming weeks.......Fingers crossed !!
Good luck everyone.
I'm no longer going to waste my time talking to you. Your reply quite frankly shows your total ignorance . If you had indeed you had looked at all research reports on Roquefort by market professionals and indeed studied all presentations by Roquefort you will see that you're wrong but I know you won't.....................so goodbye
And still no answer to my questions!!!!.
I am sorry, because I've spent 30 years as an Institutional Equity salesman promoting companies to fund managers across Asia, Europe ans the US. I have experience of failed management, which in HK is particularly prevalent . I'm very aware of the articles re Ajan, and I've researched much before investing in ROQ . I was first put on to Roquefort by a very wealthy and successful Family fund in Singapore but based in Switzerland.
Any Investors reading this should take note. I believe that Roquefort should and will most probably be sold at one pound sterling within this year.
Reason.....any company entering clinical trials is worth 55M sterling( this is not conjecture. It's fact) That alone equates to 40 pence price on the stock. ROQ have two, both taken on by the UK's biggest diagnostic company and one of the world's leaders. By December, at latest, and of course if successful this value will be recognized.
They have three more potentials which are rapidly realizing their value . The same as above applies. In the wings are many institutional investors. I can tell you from experience that no public money can be invested in Roquefort at it's value today. All public funds have investment criteria. ROQ falls short for two reasons;
1. Market cap is too small . It's a micro cap. This precludes most funds.
2. Volume of trades or LIQUIDITY ( all public money can't invest more than it can sell within two to thee days should it need to realize cash for the share holders.
But once a diagnostic or big Farma company makes a bid, that pound is easy.
I do however offer some sanity here. It may not happen of course, but the risk reward ratio in heavily in favor of ROQ now.
At 8 pence the CEO, a VC Company and a Japanese Pharmaceutical Company took a placement at 14 pence 75% market price. I've completed many placements in my career. Every one has been at a discount to market price in order to persuade investors to get in. Ajan didn't want any investor to be diluted, and he put his money in at this price.
Randox. The biggest UK diagnostics company has put it's weight behind ROQ.
I'm very hopeful for it's success, and It's my biggest weighting in my investment portfolio by a long way.
By the way. I'm Stephen Clemenson. Clemensonsteve@gmail.com should ytou want to talk privately re investments, or to check my profile.
You'll only have to wait a few more months before all your arguments are proven to be null and void. I do still wonder what makes you spend so much time on a company that you're not even invested in.......hahahahha
Nothing better to do I guess
I understand that you have your personal doubts, but the most obvious thing to look at is the recent Randox deal. The biggest diagnostics company in the UK and one of the Worlds leaders in its field has real reason to believe in the potential success of Roquefort and it's decision is based on science, not spurious articles written by who actually ?? Nobody I suspect
If you mail the PR company for ROQ with your doubts, and provided that you have a genuine interest in the company you will get a call from the CEO and he can answer all questions very easily. I'm an investor and have had such a conversation. The article was written by someone very much apposed to stem cell research on religious grounds and has been silenced by the threat of legal action. You should also consider the very extensive due diligence that the company researched on him prior to him being appointed CEO.